Le Lézard
Classified in: Health
Subject: FDA

Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease

SAN DIEGO, April 24, 2019 /PRNewswire/ -- Belite Bio, a drug development company targeting currently untreatable conditions in ophthalmology and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration.  LBS-008 will be one of the first drugs to graduate from the US National Institute of Health's (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which has funded LBS-008's discovery and development, and will continue to provide support and funding until the completion of its Phase 1 single ascending dose (SAD) clinical trial.

"Initiation of the Phase 1 trial is an important milestone for LBS-008, which was funded by the NIH Blueprint Program starting from lead optimization to a preclinical proof of concept," said Dr. Konstantin Petrukhin, Associate Professor of Ophthalmic Science at Columbia University Medical Center, and inventor of the technology. "LBS-008 is expected to bring hope to millions of patients suffering from untreatable forms of macular degeneration."

"We are excited to announce the start of this Phase 1 trial in the US together with the NIH," said Dr. Tom Lin, Chairman of Belite Bio. "We're encouraged by the ongoing favorable regulatory view of our technology, including a systematic review published by the UK National Institute for Health Research identifying reduction of RBP4 as the most promising treatments for dry AMD and Stargardt disease. We plan to continue to work closely with our collaborators to the next clinical and regulatory milestone."

About LBS-008
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins (A2E) in the eye that cause Stargardt disease and contribute to atrophic Age-related Macular Degeneration (dry AMD).

Belite Bio holds the worldwide exclusive rights for LBS-008. LBS-008 received US and EU orphan drug designation (ODD) in 2017 and 2018, and rare pediatric disease designation (RPD) from the FDA in 2018 for the treatment of Stargardt disease.

About Belite Bio
Belite Bio, a subsidiary of Lin BioScience, is a San Diego based clinical stage biopharmaceutical company targeting untreatable diseases, including age-related macular degeneration, Stargardt disease, and liver diseases. For more information, please visit www.belitebio.com.


SOURCE Belite Bio, Inc

These press releases may also interest you

at 02:05
Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the...

at 02:00
Templeton Apus, the London and Vienna-based digital media and global intelligence provider, has brought its Cancer Stat intelligence platform out of stealth mode. Cancer Stat provides cancer patients worldwide with essential groundbreaking cancer...

at 02:00
Araim Pharmaceuticals,  Inc. is pleased to announce the appointment of Ferdinand "Ferry" Breedveld, MD, PhD, the Chairman of the Board at Araim, as the organization's acting Chief Executive Officer. Dr. Breedveld brings more than 40 years of...

at 02:00
MindMeld Studios, a national preferred online educational and compliance provider, in partnership with the law firm of Wilson Elser Moskowitz Elderman and Dicker, LLP, a national legal defense firm, announces today the launch of sexual harassment...

at 01:33
Over 300 most influential global industry leaders convened in the Nansha district of Guangzhou, China from November 18 to 20 for the second East Tech West, a global forum organized by CNBC. Its focus is on the innovation and development of such...

at 01:00
With the latest and updated market insights mentioned in the report, businesses can concentrate to enhance their marketing, promotional and sales strategies. Business market research report help you stay up-to-date about the entire market and offer...

News published on 24 april 2019 at 10:15 and distributed by: